{
    "clinical_study": {
        "@rank": "139394", 
        "arm_group": [
            {
                "arm_group_label": "SEP-225289 4mg", 
                "arm_group_type": "Experimental", 
                "description": "SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses"
            }, 
            {
                "arm_group_label": "SEP-225289 8mg", 
                "arm_group_type": "Experimental", 
                "description": "SEP-225289 8mg once daily taken as  a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "4 capsules of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder\n      (ADHD)."
        }, 
        "brief_title": "Adult Attention Deficit Hyperactivity Disorder", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Adult Attention Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study\n      evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4\n      or 8 mg SEP 225289 once daily [QD]) versus placebo over a 4 week treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject meets Diagnostic and Statistical Manual of Mental Disorders Fourth Edition;\n             Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD (inattentive,\n             hyperactive, or combined subtype) established by a comprehensive psychiatric\n             evaluation that reviews DSM-IV-TR criteria. Diagnosis is confirmed by Conners' Adult\n             ADHD Diagnostic Interview (CAADID) Part 2.\n\n          -  Subject currently taking medication (stimulant or nonstimulant) for the control of\n             ADHD symptoms has an ADHD RS-IV score of \u2265 22 at screening.\n\n          -  Subject currently not taking any medication for the purpose of controlling ADHD\n             symptoms has an ADHD RS-IV score of \u2265 26 at screening.\n\n          -  Subject has a CGI-S score of \u2265 4 at screening.\n\n          -  Subject has a lifetime history of treatment with at least one medication for ADHD\n             (stimulant or nonstimulant). Subjects may be either medicated or unmedicated for ADHD\n             at the time of screening (all ADHD medications must be washed out during screening).\n\n          -  Subject has a negative breath alcohol test and a negative urine drug screen (UDS) for\n             any illicit drug at screening, unless a false positive is suspected, in which case\n             the UDS will be repeated. If the subject has a positive drug screen for ADHD\n             medications (ie, methylphenidate or amphetamine) at screening; the subject must have\n             a negative UDS after a washout period at least 3 days prior to baseline.\n\n          -  Subject is male or a non-pregnant, non-lactating female.\n\n          -  Female subjects must have a negative serum pregnancy test at screening; women who are\n             post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those\n             who have undergone hysterectomy or bilateral oophorectomy will be exempted from the\n             pregnancy test.\n\n          -  Female subjects of childbearing potential and male subjects with female partners of\n             child-bearing potential must agree to use an effective and medically acceptable form\n             of birth control throughout the study period and for one month (30 days) after study\n             completion. Medically acceptable and effective contraceptives include abstinence,\n             prescription hormonal contraceptives (oral, patch, vaginal ring, implant, or\n             injection), diaphragm with spermicide, intrauterine device (IUD), condom with\n             spermicide, surgical sterilization, or vasectomy. For male subjects adequate\n             contraception is defined as abstinence or continuous use of 2 barrier methods of\n             contraception (eg, spermicidal condom).\n\n          -  Subject is 18 to 55 years old, inclusive, at the time of informed consent. 11.\n             Subject can read well enough to understand the informed consent form and other\n             subject materials.\n\n        Exclusion Criteria:\n\n          -  Subject has a DSM-IV-TR diagnosis of ADHD not otherwise specified.\n\n          -  Subject is receiving adequate benefit from current ADHD medication in the opinion of\n             the investigator.\n\n          -  Subject has an Axis I disorder other than ADHD that has been the primary focus of\n             treatment at any time during the 12 months prior to screening.\n\n          -  Subject has a past history of, or current presentation consistent with, bipolar\n             disorder (including bipolar I, bipolar II, and bipolar not otherwise specified\n             [NOS]), schizophrenia, schizoaffective disorder, or any other psychotic disorder.\n\n          -  Subject has a history of drug dependence or substance abuse (excluding nicotine and\n             caffeine) within the 12 months prior to screening, as defined by the DSM-IV-TR\n             criteria.\n\n          -  Subject has a current Axis II disorder per DSM-IV-TR criteria.\n\n          -  Subject has a history of epilepsy, seizures (except childhood febrile seizures),\n             unexplained syncope or other unexplained blackouts (except single incident), or head\n             trauma with loss of consciousness lasting more than 5 minutes.\n\n          -  Subject has a currently active medical condition (other than ADHD) that, in the\n             opinion of the investigator, could interfere with the ability of the subject to\n             participate in the study.\n\n          -  Subject is currently taking an antidepressant medication (eg, bupropion, selective\n             serotonin reuptake inhibitor [SSRI]/ serotonin norepinephrine reuptake inhibitor\n             [SNRI], monoamine oxidase [MAO] blocker, tricyclic, etc) or St. John's Wort.\n\n          -  Subject is currently taking or has taken within the previous 6 months an\n             anticonvulsant medication (eg, phenytoin, carbamazepine, lamotrigine, valproic acid,\n             etc); antipsychotic medication; or lithium (any lithium preparation or formulation).\n\n          -  Subject is currently taking an alpha-2 adrenergic receptor agonist (including\n             clonidine and guanfacine).\n\n          -  Subject has a Body Mass Index (BMI) less than 18 or greater than 35 kg/m2 (refer to\n             Appendix V)\n\n          -  Subject answers \"yes\" to \"Suicidal Ideation\" item 4 (active suicidal ideation with\n             some intent to act, without specific plan) or item 5 (active suicidal ideation with\n             specific plan and intent) on the C-SSRS assessment at screening (in the past month).\n             Subjects who answer \"yes\" to this question must be referred to the Investigator for\n             follow-up evaluation.\n\n          -  Subject has attempted suicide within 2 years prior to the screening period.\n\n          -  Subject has history of positive test for Hepatitis B surface antigen or Hepatitis C\n             antibody. Note: Subjects with a history of a positive test for Hepatitis B surface\n             antigen or Hepatitis C antibody may be enrolled in the study if they have liver\n             function test results at screening within the normal range.\n\n          -  Subject is known to have tested positive for human immunodeficiency virus (HIV).\n\n          -  Subject has a clinically significant abnormality on screening evaluation including\n             physical examination, vital signs, ECG, or laboratory tests that the investigator in\n             consultation with the medical monitor considers to be inappropriate to allow\n             participation in the study.\n\n          -  The subject's screening ECG shows a corrected QT interval using Fridericia's formula\n             (QTcF) of \u2265 450 msec for male subjects or \u2265 470 msec for female subjects.\n\n          -  The subject's screening hematology results show an alanine aminotransferase (ALT) or\n             aspartate aminotransferase (AST) value \u2265 2 times the upper limit of normal (ULN), or\n             a blood urea nitrogen (BUN) value \u2265 1.5 times the ULN for the reference lab.\n\n          -  Subject who is currently participating or has participated in a clinical trial within\n             the last 180 days or who participated in more than 2 clinical trials within the past\n             year. This includes studies using marketed compounds or devices.\n\n          -  Subject is at high risk of non-compliance in the investigator's opinion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "341", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692782", 
            "org_study_id": "SEP360-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SEP-225289 4mg", 
                    "SEP-225289 8mg"
                ], 
                "description": "SEP-225289 4mg once daily", 
                "intervention_name": "SEP-225289", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "SEP-225289 4mg", 
                    "SEP-225289 8mg"
                ], 
                "description": "SEP-225289 8mg once daily", 
                "intervention_name": "SEP-225289", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ADHD", 
            "Attention deficit hyperactivity disorder"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encino", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91316"
                    }, 
                    "name": "Pharmacology Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92645"
                    }, 
                    "name": "Collaborative Neuroscience Network Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irvine", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92612"
                    }, 
                    "name": "University of California at Irvine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Alamitos", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90720"
                    }, 
                    "name": "Pharmacology Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92660-2452"
                    }, 
                    "name": "Pharmacology Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }, 
                    "name": "Excell Research, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Ana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92701"
                    }, 
                    "name": "Neuropsychiatric Research Center of Orange County"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34201"
                    }, 
                    "name": "Florida Clinical Research Center, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32216"
                    }, 
                    "name": "Clinical Neuroscience Solutions Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Florida Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33334"
                    }, 
                    "name": "Research Centers of America, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sanford", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32771"
                    }, 
                    "name": "Medical Research Group of Central Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Atlanta Center for Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30030"
                    }, 
                    "name": "iResearch Atlanta, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "Goldpoint Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "73103"
                    }, 
                    "name": "IPS Research Company"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester Hills", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48307"
                    }, 
                    "name": "Rochester Center for Behavioral Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Charles", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63301"
                    }, 
                    "name": "Midwest Research Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cherry Hill", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08002"
                    }, 
                    "name": "Center for Emotional Fitness"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11214"
                    }, 
                    "name": "Brooklyn Medical Institutes, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke Child and Family Study Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45408"
                    }, 
                    "name": "Midwest Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Oregon Center for Clinical Investigations, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Media", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19063"
                    }, 
                    "name": "Suburban Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "Clinical Neuroscience Solutions"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austine", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Future Search Clinical Trials, LP"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herndon", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "20170"
                    }, 
                    "name": "NeuroScience, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98033"
                    }, 
                    "name": "Eastside Therapeutic Resource"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Summit Research Network, LLC-Seattle"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)", 
        "overall_official": {
            "affiliation": "Sunovion", 
            "last_name": "CNS Medical Director, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline at Week 4 in ADHD symptoms measured with the ADHD Rating Scale Version IV with adult prompts (ADHD RS IV)", 
            "safety_issue": "No", 
            "time_frame": "4 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692782"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in ADHD symptoms measured with the ADHD RS IV at Weeks 1, 2, 3, and 6.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, and 6"
            }, 
            {
                "measure": "Change from baseline in Clinical Global Impression - Severity of Illness scale (CGI S) at Weeks 1, 2, 3, 4, and 6.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, and 6"
            }, 
            {
                "measure": "Change from baseline in the inattentiveness and hyperactivity subscales of the ADHD RS IV at Weeks 1, 2, 3, 4, and 6", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, and 6"
            }, 
            {
                "measure": "The percentage of responders at Weeks 1, 2, 3, 4, and 6. A responder is defined as a subject with a \u2265 30% improvement in ADHD symptoms compared with baseline as measured by the ADHD RS IV.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, and 6"
            }, 
            {
                "measure": "Change from baseline in cognition as measured by the CDR Computerized Cognitive Assessment System at Weeks 2, 4, and 6.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4, and 6"
            }, 
            {
                "measure": "Change from baseline in the WRAADDS as measured at Weeks 1, 2, 3, 4, and 6.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 3, 4, and 6"
            }
        ], 
        "source": "Sunovion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sunovion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}